Merck Sharp & Dohme (MSD) on Friday said its COVID antiviral molnupiravir has cut the risk of hospitalization or death in Phase 3 clinical ...

Molnupiravir is for treatment of adult patients hospitalised with COVID-19, under certain conditions, a press release from the city-based d...

According to one of the conditions, as post marketing surveillance the companies will have to submit periodic safety update reports to the ...

The recommended dose of molnupiravir is 800 mg twice a day for five days. With companies planning to launch 200 mg capsules, a patient will...

Union health minister Mansukh Mandaviya said 13 companies in India will manufacture the drug approved for restricted use under emergency si...

Molnupiravir is the first COVID-19 drug authorised by the Drugs Controller General of India (DCGI) for the treatment of COVID-19 infection ...

The drug firm said it is able to manufacture the active pharmaceutical ingredient (API) as well as the formulation for Molnupiravir, and ha...

Drug maker Cipla said it will soon make molnupiravir capsules available at all leading pharmacies and Covid treatment centers across the co...

Torrent Pharmaceuticals on Tuesday said it will launch MSD and Ridgeback's molnupiravir under the brand name Molnutor in India for the trea...

Earlier this year, the Mumbai-based drug major had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply ...

The analysis of latest data on efficacy is much less than the previous interim analysis announced by the company which was based on data fr...

The company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COV...

Natco has conducted Phase III trials of molnupiravir and submitted the trial results to the drug regulator this month. "We have submitted p...

The Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug. Merck has separately e...

One promising drug that could improve things is molnupiravir, an antiviral that's moving into the final stages of testing in humans. Resear...

Molnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...

The development comes close on the heels of findings announced by the researchers that Molnupiravir was found effective for treating the pa...